Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Regeneron does not undertake any obligation ... For my remarks today, I will review some of our key performance drivers, then briefly discuss a few of our more differentiated pipeline ...

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...

Regeneron Pharmaceuticals ... to expand Dupixent’s label to include chronic spontaneous urticaria is under review in the United States, with a target action date of April 18, 2025.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

and diabetic macular edema are under FDA review with a target action date of April 20, 2025, to potentially extend dosing intervals for Eylea HD up to every 24 weeks. Regeneron plans to submit a ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...

Shakas & Shoutouts celebrates the good people, things, and events happening in our local community, here and abroad.Shakas & ...

Some companies have announced diversity rollbacks — but many more are deleting or softening language from their investor ...

Patients with the ultra-rare rare disease CHAPLE could have a first approved treatment in the summer, now that the FDA has started its review of Regeneron’s dug candidate pozelimab. CHAPLE ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...